A “Disclosure Defense” in Liability Law

In this time of liability reform, pharma deserves the chance to align its economic interests with its ethical obligations to the patient.

Related Content:

Process and ScalingQuality SystemsPharmaceutical Technology-03-02-2005

FDA Commissioner Applauds Florida Restriction on 7-OH Opioids

FDA Grants Approval to Celltrion for Expanded Indication of Actemra Biosimilar to Treat CRS

FDA Moves to Strengthen Drug Supply Chain with PreCheck Program